- Previous Close
3.8700 - Open
3.9400 - Bid 3.8200 x --
- Ask 3.8300 x --
- Day's Range
3.8000 - 3.8700 - 52 Week Range
1.6100 - 5.4200 - Volume
54,715,000 - Avg. Volume
133,701,470 - Market Cap (intraday)
18.923B - Beta (5Y Monthly) 0.74
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1500 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date May 30, 2023
- 1y Target Est
--
Hubei Biocause Pharmaceutical Co., Ltd. primarily provides life and motor insurance products in China. It also engages in the pharmaceutical, chemical, and new energy fuel businesses. In addition, the company is involved in the contract research and production of APIs, intermediates, and formulations, including tablets, granules, capsules, etc.; and provision of chemicals comprising dimethyl ether gas and a-chloropropionyl chloride. It exports its products to approximately 85 countries, including the United States, the European Union, and internationally. The company is based in Jingmen, China.
www.biocause.com/1,765
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 000627.SZ
View MorePerformance Overview: 000627.SZ
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 000627.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 000627.SZ
View MoreValuation Measures
Market Cap
18.92B
Enterprise Value
10.59B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.46
Price/Book (mrq)
0.87
Enterprise Value/Revenue
0.25
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-1.90%
Return on Assets (ttm)
-0.45%
Return on Equity (ttm)
-4.32%
Revenue (ttm)
40.7B
Net Income Avi to Common (ttm)
-771.87M
Diluted EPS (ttm)
-0.1500
Balance Sheet and Cash Flow
Total Cash (mrq)
10.77B
Total Debt/Equity (mrq)
48.76%
Levered Free Cash Flow (ttm)
-5.06B